Detailed Mechanistic Analysis of Gevokizumab, an Allosteric Anti–IL-1β Antibody with Differential Receptor-Modulating Properties

Hassan Issafras; John A. Corbin; Ira D. Goldfine; Marina K. Roell

doi:10.1124/jpet.113.205443

Research ArticleCellular and Molecular

Detailed Mechanistic Analysis of Gevokizumab, an Allosteric Anti–IL-1β Antibody with Differential Receptor-Modulating Properties

Hassan Issafras, John A. Corbin, Ira D. Goldfine and Marina K. Roell

Journal of Pharmacology and Experimental Therapeutics January 2014, 348 (1) 202-215; DOI: https://doi.org/10.1124/jpet.113.205443

Hassan Issafras

XOMA Corporation, Preclinical Department, Berkeley, California

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

John A. Corbin

XOMA Corporation, Preclinical Department, Berkeley, California

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Ira D. Goldfine

XOMA Corporation, Preclinical Department, Berkeley, California

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Marina K. Roell

XOMA Corporation, Preclinical Department, Berkeley, California

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Info & Metrics
eLetters
PDF + SI
PDF

Submit a Response to This Article

Compose eLetter

Title *

Contents

More information about text formats

Plain text

No HTML tags allowed.
Web page addresses and e-mail addresses turn into links automatically.
Lines and paragraphs break automatically.

Author Information

Contributors
First Name and Middle Initial * First or given name, e.g. 'Peter'. Last Name * Your last, or family, name, e.g. 'MacMoody'. Email Address * Your email address, e.g. higgs-boson@gmail.com Occupation * Your role and/or occupation, e.g. 'Orthopedic Surgeon'. Affiliation * Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.

Statement of Competing Interests

Competing interests? *

Yes

Please describe the competing interests

Vertical Tabs

Jump to comment:

No eLetters have been published for this article.

PreviousNext

In this issue

Journal of Pharmacology and Experimental Therapeutics

Vol. 348, Issue 1

1 Jan 2014

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author
Editorial Board (PDF)
Front Matter (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Detailed Mechanistic Analysis of Gevokizumab, an Allosteric Anti–IL-1β Antibody with Differential Receptor-Modulating Properties

Message Subject (Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics

Message Body (Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Citation Tools

Research ArticleCellular and Molecular